SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Agrees to Review Cell Therapeutics, Inc. Application

August 24, 2009 | 
1 min read
Xconomy.com -- Cell Therapeutics, the Seattle-based developer of cancer drugs, said today that the FDA has agreed to review the company’s application to market pixantrone for non-Hodgkin’s lymphoma in the U.S.
Regulatory
MORE ON THIS TOPIC
Human kidney made out of lines. Medical Concept. 3D Rendering.
Kidney disease
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
September 23, 2026
 · 
2 min read
 · 
Annalee Armstrong
FDA
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026
 · 
2 min read
 · 
Jef Akst
Illustration showing businessman trying to create his own road
FDA
Compass vows to press on with FDA application despite new trial request
September 22, 2026
 · 
3 min read
 · 
Annalee Armstrong
FDA
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
September 16, 2026
 · 
1 min read
 · 
Jef Akst